Overview

Eculizumab for Prevention of Antibody-Mediated Rejection in ABO-Incompatible Living Donor Kidney Transplantation

Status:
NOT_YET_RECRUITING

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

The aim of this study is to determine whether a single dose of eculizumab can effectively prevent antibody-mediated rejection in recipients undergoing living donor kidney transplantation with a different ABO blood group type than their donors

Phase:

PHASE1

Details

Lead Sponsor:

Tao Lin

Treatments:

eculizumab